NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Kymera Therapeutics, Inc. (KYMR) Stock Analysis

Kymera Therapeutics, Inc. (KYMR) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

KYMR

$117.39

+$0.11 (+0.09%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare KYMR with… →

KYMR Key Statistics

As of Sep 4, 2026
Trading
Open
$115.09
Previous Close
$117.28
Day's Range
112.77–118.28
52-Week Range
42.22–130.05
Volume
378.60K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.97
Valuation
Market Cap
$9.66B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
91.96
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.25
Financials (FY)
Revenue (FY)
$39.21M−16.70%
Net Income (FY)
−$311.35M
Profit marginThe share of revenue left as profit after all costs and taxes.
−285.33%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
82.26M
1-Year Return
+178.18%
Dividend and dates
Earnings Date
November 3, 2026
Avg Volume
858.11K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

KYMR Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+50.87%
2025+93.41%
2024+58.01%
2023+2.00%
2022−60.69%
2021+2.40%
2020 (partial year)+86.41%

As of September 4, 2026.

KYMR Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$39.21M−$311.35M−794.0%
2024$47.07M−$223.86M−475.6%
2023$78.59M−$146.96M−187.0%
2022$46.83M−$154.81M−330.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$39.21M—−$345.54M−$311.35M−794.0%
2024$47.07M—−$256.71M−$223.86M−475.6%
2023$78.59M—−$165.53M−$146.96M−187.0%
2022$46.83M—−$161.26M−$154.81M−330.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

KYMR Valuation vs Biotechnology Median

Median of 656 stocks
MetricKYMRBiotechnology medianvs median
P/S ratio91.9615.266.0x the median
Profit margin−285.33%0.00%285.3 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 12 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Kymera Therapeutics, Inc. (KYMR) at $9.66B. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 273 employees.

The most recent close on file for KYMR is $117.39, dated September 4, 2026. That is +$0.11 (+0.09%) against the previous close. The 52-week range on file runs from $42.22 to $130.05. The latest close sits 178.04% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $39.21M. Against the prior fiscal year total of $47.07M, that is a change of −16.70%. The same year closed with a net loss of $311.35M. The reported profit margin is −285.33%. That is 285.3 percentage points below the Biotechnology median of 0%. Trailing earnings per share are −3.25.

Across the 4 fiscal years on file, revenue moves from $46.83M in 2022 to $39.21M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 91.96 times revenue. On price-to-sales that is 6 times the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The trailing one-year price return is +178.18%. Across 5 years the annualized return works out at +14.35%. Beta against the wider market is reported at 1.97. Annualized volatility over the trailing 6 years is 74.47%.

Growth & Income

No dividend is on file for KYMR.

The strongest complete calendar year on file is 2025 at +93.41%; the weakest is 2022 at −60.69%. Of the 5 complete calendar years on file, 4 finished higher. So far in 2026 the price is +50.87%.

Peer Comparison

Kymera Therapeutics, Inc. (KYMR) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Kymera Therapeutics, Inc. KYMR $9.66B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Kymera Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Visit website →